

Regulatory Announcement

Company Akers Biosciences, Inc.
TIDM AKR
Headline Issue of Equity
Released 11:31 14-Mar-08

RNS Number:1281Q
Akers Biosciences, Inc.
14 March 2008

Akers Biosciences, Inc.
("ABI" or the "Company")
Issue of Equity

ABI announces that it has issued a total of 499,056 common shares of nil par value each in the Company ("Shares"). 50,623 common shares of nil par value have been issued to satisfy payment in lieu of cash for consulting services to the Company and 448,433 common shares of nil par value have been issued as a result of the exercise of warrants.

Application has been made to the London Stock Exchange for the Shares to be admitted to trading on AIM, which is expected to take place on 20 March 2008.

Following Admission, the Company's enlarged issued share capital will comprise 68,554,220 ordinary shares with voting rights. The Company does not hold any shares in treasury. This figure of 68,554,220 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Contact:

Thomas A. Nicolette +1 856 848 8698
President

Alasdair Younie +44 (0) 20 7012 2000
Arbuthnot Securities Limited

END